NFL Biosciences SA

NFL Biosciences SA is a biopharmaceutical company based in Castelnau-le-Lez, France, specializing in the research and development of botanical drug candidates for the treatment of addictions. The company's mission is to deliver new, natural therapeutic solutions that are both safer and more effective for a global population, including those in low- and middle-income countries.

The company's pipeline includes several key drug candidates. NFL-101, a nicotine-free tobacco leaf protein extract, is currently undergoing Phase 2b clinical trials for smoking cessation. NFL-301 is a drug candidate in the preclinical stage aimed at reducing alcohol consumption, with a PRE-IND application filed with the FDA in 2023. Additionally, NFL Biosciences is developing NFL-102, another standardized tobacco leaf extract, and has a drug development program targeting cannabis use disorders.

Recent developments include the release of new results in June 2026 for NFL-101, reaffirming its personalized approach to smoking cessation based on efficacy analyses linked to a predictive biomarker. In the same month, the company announced the successful manufacturing of a GMP clinical batch of NFL-102 and validated its industrial production chain. Three scientific communications regarding NFL-101 and NFL-102 were accepted for presentation at the 2026 SRNT-Europe Conference in July 2026. Bruno Lafont serves as the Chief Executive Officer and co-founder.